This study will evaluate the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL)
(MK-7655A) compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed
with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventilator-Associated Bacterial
Pneumonia (VABP). The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ as
measured by the incidence rate of all-cause mortality through Day 28 post-randomization.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.